- Learn
Velox Peptides Guides
Educational resources for researchers working with HPLC-verified peptides - plain-English explainers, side-by-side compound comparisons, a research-terms glossary, and frequently asked questions. Everything you need to understand the science and the documentation behind each compound.
Last updated: 15 July 2026
For scientific reference only - not medical advice. All content is derived from peer-reviewed preclinical and clinical research. Summaries are provided for scientific reference, not medical advice, diagnosis, or treatment. All compounds are for in vitro research use only. Not for human or veterinary consumption.
Recently updated
Retatrutide Arrhythmia Signal: TRANSCEND-T2D-1
STAT News (6 Jun 2026): TRANSCEND-T2D-1 reported arrhythmia in 7 of 403 retatrutide participants vs 0 of 134 on placebo, plus 3 major CV events vs 0.
PCAC Hearing: BPC-157, TB-500 & 5 More Peptides (July 2026)
The FDA’s Pharmacy Compounding Advisory Committee meets 23–24 July 2026 to evaluate seven peptides for 503A bulk-compounding status. What researchers need to know.
Sandoz Files First Generic Tirzepatide ANDA
The FDA accepted Sandoz’s abbreviated applications for generic tirzepatide (Mounjaro & Zepbound) on 29 June 2026 — the first generic filing for a GIP/GLP-1 dual agonist.
TRIUMPH-1: Retatrutide 80-Week Obesity Data
The pivotal 80-week Phase 3 read-out (n=2,339): retatrutide 12 mg reported 28.3% body-weight reduction vs 2.2% placebo. Full data presented at ADA 2026.
Retatrutide Dysesthesia: TRIUMPH-4 Safety Signal
TRIUMPH-4 (ADA 2026) reported dysesthesia in 20.9% on retatrutide 12 mg vs 0.7% placebo — a class-unique signal not seen with tirzepatide or semaglutide.
Oral Semaglutide: MHRA UK Approval (June 2026)
The MHRA approved oral semaglutide (Wegovy tablet) for UK weight management on 11 June 2026 — the first oral GLP-1 in Europe. OASIS 4 reported 13.6% weight loss at 64 weeks.
Peptide Research Landscape 2026
TRIUMPH-1, SYNCHRONIZE-1, orforglipron approval, oral semaglutide MHRA, FDA reclassification and the upcoming PCAC hearing — every major 2026 development in one hub.
Regulatory & News
FDA Peptide Reclassification 2026
Twelve peptides including BPC-157, TB-500 and Semax removed from FDA 503A Category 2 in April 2026. Full list, timeline and context for researchers.
FDA PCAC 2026: BPC-157, TB-500 & 5 More
The PCAC meets 23–24 July 2026 to vote on 503A Category 1 status for seven peptides. Public comments closed 9 July. Guide to each compound’s evidence dossier.
FDA Flags Peptide Evidence Gaps (2026 Briefing)
The FDA’s 29 June 2026 briefing documents found no human data for TB-500 and KPV, and insufficient evidence for BPC-157, ahead of the PCAC vote.
Retatrutide FDA Approval Timeline 2026–2028
NDA filing expected Q4 2026, FDA approval estimated late 2027, MHRA UK ~2028. Phase 3 milestones, pending trials and research-use context.
Retatrutide FDA Expanded Access (2026)
In June 2026 the FDA granted compassionate-use expanded access to retatrutide for one patient outside Phase 3 trials. What it means for the approval timeline.
2026 Conference & Trial Data
TRIUMPH-1 Phase 3: Retatrutide’s Pivotal Obesity Trial
Design, reported results and research context for the headline 2026 Phase 3 read-out — 28.3% body-weight reduction at 80 weeks on the 12 mg dose.
Retatrutide Cardiometabolic Markers (ADA 2026)
TRIUMPH-1 Phase 3 data at ADA 2026: retatrutide 12 mg reduced triglycerides 41%, non-HDL cholesterol 24.2% and systolic BP 12.3 mmHg at 80 weeks.
Retatrutide Dysesthesia: TRIUMPH-4 Signal
TRIUMPH-4 (ADA 2026) reported dysesthesia in 20.9% on retatrutide 12 mg vs 0.7% placebo — a class-unique adverse event not seen with other incretin agonists.
Retatrutide Arrhythmia Signal: TRANSCEND-T2D-1
TRANSCEND-T2D-1 (Lancet, ADA 2026) found arrhythmia in 7 of 403 retatrutide participants vs 0 of 134 placebo, plus 3 major cardiovascular events vs 0.
Elecoglipron: Oral GLP-1 Phase 2 (ADA 2026)
SOLSTICE & VISTA Phase 2 data (ADA 2026, The Lancet): AstraZeneca’s oral GLP-1 achieved −1.9% HbA1c and up to 10.5% weight loss at 26 weeks. Phase 3 planned.
Lilly’s Quintuple Agonist: 5 Receptors (ADA 2026)
Poster 2839-LB (ADA 2026): VRX-0075 targets GLP-1, GIP, glucagon, amylin and calcitonin receptors and outperformed retatrutide for weight loss in obese rats. Preclinical only.
Research Summary
GLP-1 & Epigenetic Aging: 2026 RCT Evidence
A 2026 Nature Communications RCT reports semaglutide reduced biological age by 3.1–4.9 years across multiple epigenetic clocks in a 32-week randomised trial.
GLP-1 Agonists & Autoimmune CVD Data (2026)
Target trial emulation (JAHA, June 2026; n=26,000): GLP-1 RA use linked to 44% lower mortality and fewer cardiac events in obesity with autoimmune disease.
Tirzepatide & Brown Fat: TABFAT Trial (ENDO 2026)
TABFAT trial (ENDO 2026, n=34): tirzepatide raised PET/CT-detected brown adipose tissue activity from 41% to 65% in 24 weeks, independent of weight loss.
Research Summary
Semaglutide & Biological Aging: Epigenetic Study
Nature Communications RCT (2026): semaglutide reduced biological age by 3–5 years on epigenetic clocks — the first randomised evidence of GLP-1 anti-ageing effects.
Retatrutide vs Survodutide: Liver-Fat Data
Survodutide’s Phase 3 SYNCHRONIZE-MASLD liver-fat data (Nature Medicine, June 2026) compared with retatrutide’s own Phase 2a MASLD trial results.
Retatrutide vs Berobenatide & Enicepatide
Pfizer’s berobenatide and Roche’s enicepatide posted ADA 2026 Phase 2 data (15.9% and 22.7% weight loss) — how they compare with retatrutide’s TRIUMPH-1 numbers.
MOTS-c Phase 2a Human Trial (2026)
Hudson Biotech’s Phase 2a trial (NCT07505745) is MOTS-c’s first human efficacy study, testing insulin sensitivity in prediabetes and obesity.
Retatrutide & Cognition: Preclinical Study
A 2026 bioRxiv preprint reports retatrutide preserved memory and cut hippocampal TNF-α in diabetic rats. Preclinical, not yet peer-reviewed.
Educational Guides
Peptide Research Landscape 2026
TRIUMPH-1, SYNCHRONIZE-1, orforglipron approval, oral semaglutide MHRA, FDA reclassification and the upcoming PCAC hearing — every major 2026 development in one hub.
Guide
What Are Research Peptides? A Plain-English Primer
A simple introduction to what peptides are, how they differ from proteins, and why they are supplied strictly as in vitro research reagents.
Guide
Peptide Storage & Handling in the Lab
How to keep lyophilised and reconstituted research peptides stable - temperature, light, desiccants, and good laboratory practice.
Guide
Bacteriostatic Water Explained
What bacteriostatic water is, how it differs from sterile water, and why it is commonly used to reconstitute peptides in the lab.
Guide
How Peptides Are Tested: HPLC & Mass Spec
A plain-English walk through the two main analytical methods used to confirm a peptide’s purity and identity.
Guide
Peptide Reconstitution Guide
A technical reference for dissolving lyophilised peptides - concentration calculations, sterile handling, and storage guidance.
Guide
How to Read a Certificate of Analysis
What HPLC purity figures mean, how to interpret a CoA, and why mass spectrometry confirmation matters.
Guide
How to Buy Research Peptides in the UK
What to look for in a UK supplier - HPLC documentation, CoA transparency, batch testing, and shipping standards.
Guide
Are Research Peptides Legal in the UK?
The legal status of research peptides under UK law and what “for research use only” means for researchers.
Guide
Most Popular Research Peptides UK (2026)
The most-studied research peptides in the UK in 2026, by research area — tissue repair, incretin/metabolic, neuropeptide, growth-hormone axis and oxidative stress.
Guide
What Makes a Peptide Novel?
A plain-English explainer on sequences, how novelty is checked against databases, and why synthesisability and chain length matter for research peptide design.
Guide
AI Peptide Design, Explained
How an AI model turns a plain-English research target into novel, scored peptide sequences — and where machine-learning fits in an in-vitro research workflow.
Comparisons
SURMOUNT-5: Tirzepatide vs Semaglutide
The first major head-to-head trial of tirzepatide against semaglutide for weight reduction - reported results, trial design and what they mean for the field.
Comparison
BPC-157 vs TB-500
Two tissue-repair peptides compared side by side - mechanisms, study models, and the rationale for combining them in research.
Comparison
Semax vs Selank
Two Russian neuropeptides compared - their BDNF and GABA pathway mechanisms and combined research rationale.
Comparison
CJC-1295 vs Tesamorelin
Two GHRH analogues compared - half-life profiles and GH pulse amplitude data from rodent models.
Retatrutide vs Tirzepatide vs Semaglutide
Three incretin receptor agonists compared - receptor targets and the difference between single, dual, and triple agonism.
Is Retatrutide a GLP-1?
Answer-first explainer - why Retatrutide is a GLP-1 / GIP / glucagon triple agonist, with plain-English diagrams.
Comparison
Selank vs DSIP
An anxiolytic neuropeptide compared with a sleep-modulating peptide - distinct mechanisms studied in rodent models.
Comparison
GHK-Cu vs BPC-157
A copper-tripeptide compared with a pentadecapeptide - their differing roles in tissue-remodelling and repair research.
Retatrutide vs Ozempic (Semaglutide)
Triple GLP-1/GIP/glucagon agonism vs single GLP-1 agonism — receptor mechanisms, trial weight-loss data and research context compared side by side.
Retatrutide vs Wegovy (Semaglutide)
Triple agonism vs single GLP-1 agonism for weight management — TRIUMPH-1 vs STEP trial data, mechanisms and where each stands in 2026.
Glossary & FAQs
Glossary
Research Peptide Glossary (A–Z)
Plain-English definitions of the key scientific and laboratory terms you will meet across our guides and research summaries.
FAQ
Frequently Asked Questions
Answers to common questions about ordering, shipping, documentation, and the research-use-only nature of our compounds.
Research Summaries
Survodutide (BI 456906)
A GLP-1/glucagon dual agonist now in Phase 3. SYNCHRONIZE-1 reported 16.6% weight loss at 46 weeks; LIVERAGE MASH programme ongoing. Updated with 2026 trial data.
Tirzepatide: Preclinical Research Overview
A dual GIP/GLP-1 receptor agonist with SURMOUNT-5 head-to-head data vs semaglutide. Updated with 2026 trial results and the Sandoz generic ANDA filing.
Research Summary
Ipamorelin: Preclinical Research Overview
A selective growth hormone secretagogue (ghrelin-receptor agonist) studied in GH-signalling research.
Retatrutide: Preclinical Research Overview
A GLP-1/GIP/glucagon triple agonist studied in preclinical and early clinical metabolic research.
Retatrutide Reconstitution & Dosing
Bacteriostatic water ratios, mg-per-unit concentration maths, the Phase 2 trial titration schedule and half-life - for research handling.
Retatrutide & Type 2 Diabetes Research
How the GLP-1/GIP/glucagon triple agonist is studied in glycaemic-control and type 2 diabetes research models.
Retatrutide & Sleep Apnea Research
Research context for retatrutide in obstructive sleep apnea and weight-related respiratory studies.
Retatrutide & Osteoarthritis Research
Retatrutide in obesity-related osteoarthritis research - mechanism and study context.
Retatrutide Side Effects & Tolerability
What the clinical trials reported on retatrutide adverse events and tolerability - gastrointestinal events, dose escalation and the heart-rate signal. Research summary.
Research Summary
BPC-157: Preclinical Research Overview
A synthetic pentadecapeptide studied in angiogenesis, tendon and ligament, and gastrointestinal repair models.
Research Summary
TB-500: Preclinical Research Overview
A thymosin β4 fragment studied for actin binding, cell migration, and angiogenesis in tissue-repair models.
Research Summary
Semax: Preclinical Research Overview
A neuropeptide studied for BDNF and NGF pathway activity in preclinical neuroscience models.
Research Summary
Selank: Preclinical Research Overview
A neuropeptide studied for anxiolytic effects and GABA pathway modulation in rodent models.
Research Summary
CJC-1295: Preclinical Research Overview
A modified GHRH analogue studied for growth-hormone pulse amplitude in preclinical models.
Research Summary
Tesamorelin: Preclinical Research Overview
A GHRH analogue studied for receptor activation and pulsatile GH secretion in rodent models.
Research Summary
GHK-Cu: Preclinical Research Overview
A naturally-occurring copper-tripeptide studied in dermal fibroblast and tissue-remodelling models.
MOTS-C: Preclinical Research Overview
A mitochondrially-encoded peptide studied for AMPK activation and metabolic signalling in rodent models.
Research Summary
NAD+: Preclinical Research Overview
A cellular cofactor studied for energy metabolism and sirtuin pathway activation in animal models.
Research Summary
KPV: Preclinical Research Overview
An alpha-MSH C-terminal tripeptide studied for NF-κB inhibition and mucosal inflammation models.
Research Summary
Melanotan II: Preclinical Research Overview
A melanocortin receptor agonist studied for pigmentation pathway signalling in rodent models.
Research Summary
Glutathione: Preclinical Research Overview
An endogenous tripeptide antioxidant studied for oxidative stress pathways in cellular and animal models.
Research Summary
DSIP: Preclinical Research Overview
A delta sleep-inducing neuropeptide studied for sleep modulation and stress response in rodent models.
Research Summary
Epitalon (Epithalon): Preclinical Research Overview
A synthetic pineal tetrapeptide studied for telomerase activity and melatonin-rhythm regulation in ageing research models.
How Retatrutide Works: Mechanism of Action
A research-focused breakdown of GLP-1, GIP and glucagon receptor pathways activated by LY3437943 — why triple agonism matters for metabolic research.
Retatrutide Clinical Research: All Trial Data
Summary of published retatrutide clinical research: Phase 1 (Lancet 2022), Phase 2 (NEJM 2023) and TRIUMPH Phase 3 data for LY3437943.
Browse the compound catalogue
Every compound page includes a research overview, specification table, and batch testing summary.
